ADC Therapeutics (ADCT) Treasury Shares (2019 - 2026)

ADC Therapeutics has disclosed Treasury Shares across 8 years of filings, most recently posting $205000.0 for Q1 2026.

• Treasury Shares for Q1 2026 came in at $205000.0, down 0.97% year-over-year; the trailing twelve-month figure through Mar 2026 was $205000.0 (down 0.97% YoY), and the FY2025 annual result was $205000.0, down 6.82% from the prior year.
• Treasury Shares came in at $205000.0 for Q1 2026 at ADC Therapeutics, roughly flat from $205000.0 in the prior quarter.
• In the past five years, Treasury Shares ranged from a high of $9.1 million in Q1 2026 to a low of $2.6 million in Q4 2025.
• The 5-year median for Treasury Shares is $6.5 million (2023), against an average of $5.4 million.
• Across the five-year window, Treasury Shares jumped 430.47% in 2022 and tumbled 59.33% in 2024, its largest moves.
• ADC Therapeutics' Treasury Shares stood at $679000.0 in 2022, then retreated by 20.32% to $541000.0 in 2023, then sank by 59.33% to $220000.0 in 2024, then slipped by 6.82% to $205000.0 in 2025, then changed by 0.0% to $205000.0 in 2026.
• The last three Treasury Shares figures came in at $205000.0 (Q1 2026), $205000.0 (Q4 2025), and $205000.0 (Q3 2025), per Business Quant data.